Tag: Biologics
Samsung Biologics set to thrive if BIOSECURE bill passes in US, says...
A list of companies of concern, including the Chinese CDMO giant Wuxi AppTec Ltd., is included in the bill. If the bill passes, the government will examine whether any other China-based companies should be added
Aragen operationalizes first phase of its biologics manufacturing facility in India
The non-GMP facility can undertake batch sizes upto 50 Litres and includes process development and analytical labs to support the manufacturing activities
Revolutionary rise of 3D printed medical devices shaping healthcare
Advancements in the orthopedic section of healthcare, along with its support for modern ortho biologics products and regenerative medicines, are fueling the demand for it
Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...
The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore
“There are inconstancies across biosimilar classes right now”
Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets
Biocon Biologics appoints Sandoz as distributor for Adalimumab BS Subcutaneous Injection...
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases
Biocon Biologics concludes integration of acquired biosimilars business in 120 countries
Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris.
Biocon Biologics successfully completes integration of Viatris’ biosimilar business in 31...
In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept
Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...
In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)
Biocon Biologics announces divestment of two non-core branded formulations business units
The move is in line with the company’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company